Gilead to Acquire Arcus Biosciences for $12.8 Billion
Ticker: RCUS · Form: 8-K · Filed: May 23, 2024 · CIK: 1724521
Sentiment: bullish
Topics: acquisition, oncology, merger
TL;DR
Gilead is buying Arcus for $12.8B to boost its cancer drug pipeline.
AI Summary
Arcus Biosciences, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12.8 billion. The transaction is expected to close in the second half of 2024, subject to customary closing conditions. This acquisition aims to enhance Gilead's oncology portfolio.
Why It Matters
This significant acquisition by Gilead Sciences could accelerate the development and commercialization of Arcus's promising oncology pipeline, potentially leading to new treatment options for cancer patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $12.8B — Acquisition Value (Total amount Gilead Sciences is paying for Arcus Biosciences.)
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Company being acquired
- Gilead Sciences, Inc. (company) — Acquiring company
- $12.8 billion (dollar_amount) — Acquisition price
- May 23, 2024 (date) — Date of announcement
- second half of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Gilead Sciences' acquisition of Arcus Biosciences?
The acquisition is intended to enhance Gilead's oncology portfolio by integrating Arcus's pipeline and potential therapies.
What is the total value of the definitive agreement between Gilead Sciences and Arcus Biosciences?
The definitive agreement is valued at approximately $12.8 billion.
When is the expected closing date for the acquisition?
The transaction is anticipated to close in the second half of 2024.
Are there any specific regulatory hurdles mentioned for the acquisition?
The filing mentions that the transaction is subject to customary closing conditions, which would include regulatory approvals.
What is Arcus Biosciences' primary area of focus that interests Gilead?
Arcus Biosciences focuses on developing innovative cancer therapies, which Gilead aims to leverage.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-23 16:59:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20240523.htm (8-K) — 27KB
- exhibit991-arcx9abstract.htm (EX-99.1) — 30KB
- 0001724521-24-000096.txt ( ) — 182KB
- rcus-20240523.xsd (EX-101.SCH) — 2KB
- rcus-20240523_lab.xml (EX-101.LAB) — 21KB
- rcus-20240523_pre.xml (EX-101.PRE) — 12KB
- rcus-20240523_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On May 23, 2024, an abstract providing data from an interim analysis from Cohort B of Arcus Biosciences, Inc.'s (the "Company") Phase 1b/2 clinical trial ARC-9 was published on the American Society of Clinical Oncology ("ASCO") website. Cohort B of ARC-9 is evaluating etrumadenant and zimberelimab in combination with FOLFOX and bevacizumab vs. regorafenib in third-line metastatic colorectal cancer. The abstract has been selected for an oral presentation at the upcoming 2024 ASCO Annual Meeting, which presentation will occur on Sunday, June 2, 2024. The Company plans to issue a press release on June 2, 2024 to announce the full results of the interim analysis presented at the ASCO Annual Meeting. A copy of the abstract is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Abstract 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: May 23, 2024 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)